[Demonstration of drug-specific IgE and IgG antibodies using RIA: clinical importance as shown with nomifensin (Alival)].
Serum samples from 41 patients who developed adverse reactions during therapy with nomifensine were screened by RAST-based immunoassay for specific IgE and IgG antibodies against nomifensine and three of its metabolites. The results were compared with those of 10 patients without side effects and with 8 non-treated controls. Nomifensine-specific IgE antibodies were found in none of the subjects. However, all patients treated with nomifensine (with and without side effects) had specific IgG antibodies. The antibody cross-reacted in all cases with the metabolites. The titers did not discriminate clearly between the different side reactions and only partially between the presence or absence of a side reaction. The finding of specific anti-drug IgG antibodies warrants more detailed investigation of immunological mechanisms, to determine the clinical relevance of these antibodies and identify patients at risk for serious side effects.
D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced; D000743:Anemia, Hemolytic / Q000139:chemically induced; D000917:Antibody Formation; D000918:Antibody Specificity; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004342:Drug Hypersensitivity; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007546:Isoquinolines / Q000276:immunology*; D009627:Nomifensine / Q000009:adverse effects / Q000276:immunology*; D011863:Radioimmunoassay
D007074:Immunoglobulin G; D007546:Isoquinolines; D009627:Nomifensine; D007073:Immunoglobulin E
Nachweis von arzneimittel-spezifischen IgE- und IgG-Antikörpern mittels RIA: klinische Bedeutung am Beispiel Nomifensin (Alival).